Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) - Total Liabilities
Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has total liabilities worth CN¥273.93 Million CNY (≈ $40.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Shanghai Fudan-Zhangjiang Bio-Pharmaceut annual equity growth to track the company's year-over-year net asset growth rate.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Shanghai Fudan-Zhangjiang Bio-Pharmaceut free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prashkovsky
TA:PRSK
|
Israel | ILA4.72 Billion |
|
Macmic Science & Technology Co Ltd
SHG:688711
|
China | CN¥1.48 Billion |
|
Carasso
TA:CRSO
|
Israel | ILA9.35 Billion |
|
Dor Alon
TA:DRAL
|
Israel | ILA5.70 Billion |
|
JK Paper Limited
NSE:JKPAPER
|
India | Rs47.52 Billion |
|
Replimune Group Inc
NASDAQ:REPL
|
USA | $123.05 Million |
|
Zhejiang Tongxing Technology Co. Ltd. A
SHE:301252
|
China | CN¥596.75 Million |
|
KSL Holdings Bhd
KLSE:5038
|
Malaysia | RM1.36 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688505 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual total liabilities of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥273.93 Million ≈ $40.09 Million |
-2.59% |
| 2024-12-31 | CN¥281.23 Million ≈ $41.15 Million |
-45.72% |
| 2023-12-31 | CN¥518.12 Million ≈ $75.82 Million |
-28.34% |
| 2022-12-31 | CN¥722.99 Million ≈ $105.80 Million |
+22.21% |
| 2021-12-31 | CN¥591.58 Million ≈ $86.57 Million |
+20.19% |
| 2020-12-31 | CN¥492.21 Million ≈ $72.03 Million |
-22.08% |
| 2019-12-31 | CN¥631.68 Million ≈ $92.43 Million |
+35.53% |
| 2018-12-31 | CN¥466.08 Million ≈ $68.20 Million |
+84.47% |
| 2017-12-31 | CN¥252.65 Million ≈ $36.97 Million |
+2.00% |
| 2016-12-31 | CN¥247.70 Million ≈ $36.25 Million |
-2.64% |
| 2015-12-31 | CN¥254.43 Million ≈ $37.23 Million |
+71.84% |
| 2014-12-31 | CN¥148.06 Million ≈ $21.67 Million |
-19.22% |
| 2013-12-31 | CN¥183.29 Million ≈ $26.82 Million |
-33.87% |
| 2012-12-31 | CN¥277.18 Million ≈ $40.56 Million |
+75.64% |
| 2011-12-31 | CN¥157.81 Million ≈ $23.09 Million |
+16.51% |
| 2010-12-31 | CN¥135.45 Million ≈ $19.82 Million |
+3.82% |
| 2009-12-31 | CN¥130.46 Million ≈ $19.09 Million |
+58.00% |
| 2008-12-31 | CN¥82.57 Million ≈ $12.08 Million |
+39.15% |
| 2007-12-31 | CN¥59.34 Million ≈ $8.68 Million |
+36.97% |
| 2006-12-31 | CN¥43.32 Million ≈ $6.34 Million |
+125.88% |
| 2005-12-31 | CN¥19.18 Million ≈ $2.81 Million |
-- |
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more